DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma
Posted: Thursday, September 9, 2021
“Belantamab mafodotin-blmf has the potential to shift the treatment paradigm in the heavily pretreated, anti-CD38 monoclonal antibody–exposed [relapsed or refractory multiple myeloma] patient population, [who have] a poor prognosis and few alternative treatment options,” declared Adam D. Cohen, MD, of Abramson Cancer Center, Philadelphia, and colleagues in the journal Cancer, based on their 13-month follow-up investigating longer-term efficacy and safety outcomes in the ongoing phase II DREAMM-2 study. Of note, this patient population includes those with high-risk cytogenetics and renal impairment. Single-agent belantamab mafodotin was approved by the U.S. Food and Drug Administration based on earlier DREAMM-2 results in this patient population who had received at least four prior therapies, including anti-CD38 therapy.
The extended analysis revealed a median estimated overall survival of 13.7 months in patients taking single-agent belantamab mafodotin at 2.5 mg/kg, “substantially longer than that reported in a similar population,” Dr. Cohen and co-investigators wrote. The median estimated durations of response in the overall 2.5-mg/kg group—11 months—and in patients who achieved a minimal response or better—11.7 months—are the longest reported to date in patients with triple-class–refractory multiple myeloma, they noted.
Of note, of the patients who had a clinical response and then prolonged dose delays of more than 2 months, mostly because of corneal adverse effects, 88% maintained or deepened responses during their first prolonged dose delay. Further, no new safety signals were identified during this follow-up, and the follow-up continues for long-term responders.
Disclosure: The study authors’ disclosure information can be found at acsjournals.onlinelibrary.wiley.com.
